Coronavirus Updates

Comirnaty: What’s the story behind the new Pfizer vaccine name?

US & World

FILE — A paramedic with Israel’s Magen David Adom medical service gets a vial of the Pfizer-BioNTech Covid-19 vaccine on August 24, 2021 at a vaccination centre in Holon. (Photo by Ahmad GHARABLI / AFP) (Photo by AHMAD GHARABLI/AFP via Getty Images)

(NEXSTAR) – Pfizer received full FDA approval for its vaccine and all of a sudden there’s a new vaccine name being thrown around: Comirnaty.

Comirnaty, who? It’s the same exact mRNA vaccine Pfizer has produced through the emergency use authorization, but now it’s being marketed under the new name. Comirnaty is administered in two doses, three weeks apart, just like Pfizer doses have been all along.

The vaccine name is pronounced koe-mir’-na-tee. It doesn’t exactly roll off the tongue, but neither did “Pfizer-BioNTech COVID-19 Vaccine,” which is what it was technically called before.

The name was developed by Brand Institute in conjunction with BioNTech and Pfizer, according to Fierce Pharma.

“The name is coined from COVID-19 immunity, and then embeds the mRNA in the middle, which is the platform technology, and as a whole the name is meant to evoke the word community,” Scott Piergrossi, Brand Institute president of operations and communications, told the site. 

The rebranding didn’t go unnoticed – nor unpunished – on social media.

Pfizer’s vaccine isn’t the only one with an alter ego. Moderna’s is branded as Spikevax in Europe. The one-shot Johnson & Johnson shot is technically called the Janssen COVID-19 vaccine after the American company’s Belgian subsidiary Janssen Pharmaceuticals.

For local and breaking news, weather alerts, video and more, download the FREE WOWK 13 News App from the Apple App Store or the Google Play Store.

Copyright 2021 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Download the FREE WOWK 13 News App

Washington DC Bureau

More Washington DC Bureau

Trending Stories

Don't Miss

Trending Stories